A Phase 2 interventional study of Filgotinib and Placebo to match filgotinib in Fistulizing Crohn's Disease, sponsored by Gilead Sciences. Completed at 27 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-08.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.
Among the 660 studies in Crohn Disease with a site in United States, this one is the 273rd largest by enrollment of the 528 interventional ones that give a count, is one of 37 that started in 2017, is one of 141 in phase 2, and was the 337th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:
Shattuck Labs, Inc. · Sites in United States
Ages 18–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Agomab Spain S.L.U. · Sites in United States, Serbia, United Kingdom
Ages 18+
University of Miami · Sites in United States
Ages 16–75
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
660 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 179 · Phase 3 134 · Phase 4 41
First in 1995; this study’s year is marked. 37 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 60 across the 528 interventional studies, 168 across the 128 observational. Of the 452 that completed or were terminated, 205 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
310 of 660 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
59 of the studies in Crohn Disease with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT05660746Phase 3Children's Hospital Medical Center, CincinnatiPrecise Infliximab Exposure and Pharmacodynamic Control | 2027-03-31 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
Add all 59 to your calendar (.ics) → With an account.
Among the 660 studies in Crohn Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of filgotinib as compared to placebo in establishing combined fistula response at Week 24. Participants will have the option to enter a separate Long-Term Extension (LTE) study (GS-US-419-3896; NCT02914600) if they meet eligibility requirements.
Key Inclusion Criteria:
Previously demonstrated an inadequate clinical response, loss of response to, or intolerance of at least 1 of the following agents (depending on current country treatment recommendations/guidelines):
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
Drug: Filgotinib · Drug: Placebo to match filgotinib
Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
Drug: Filgotinib · Drug: Placebo to match filgotinib
Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
Drug: Placebo to match filgotinib
Tablet(s) administered orally once daily
Also known as: GS-6034, GLPG0634
Tablet(s) administered orally once daily
Percentage of Participants Who Achieved Combined Fistula Response at Week 24
Combined fistula response at Week 24 was defined as reduction of greater than or equal to (≥) 1 from baseline in the number of draining external perianal fistula openings that were present at baseline, and absence of fluid collections \> 1 centimeter (cm) on magnetic resonance imaging (MRI) pelvis at Week 24, among participants with at least 1 draining external perianal fistula opening at baseline.
Time frame: Week 24
Percentage of Participants Who Achieved Combined Fistula Remission at Week 24
Combined fistula remission at Week 24 was defined as perianal fistula closure of all external openings that were draining at baseline, and absence of fluid collections \> 1 cm on MRI of pelvis at Week 24, among participants with at least 1 draining external perianal fistula opening at baseline.
Time frame: Week 24
Time to Clinical Fistula Response up to Week 24
Time to clinical fistula response was defined as the time interval in days from date of first dosing of study drug to the first observation (during scheduled or unscheduled clinical visits) when ≥ 1 of the draining external perianal fistula openings that were present at baseline achieves perianal fistula closure, among participants with at least 1 draining external perianal fistula opening at baseline. Participants not known to had a clinical fistula response were to have their clinical fistula response time censored at the last time that lack of clinical fistula response was documented.
Time frame: Time from treatment start to first visit when ≥ 1 of the draining external perianal fistula openings that were present at baseline achieved perianal fistula closure up to Week 24
Time to Clinical Fistula Remission up to Week 24
Time to clinical fistula remission was defined as the time interval in days from date of first dosing of study drug to the first observation (during schedule or unscheduled clinical visits) of perianal fistula closure of all external openings that were draining at baseline, among participants with at least 1 draining external perianal fistula opening at baseline. Participants not known to had a clinical fistula remission were have their clinical fistula remission time censored at the last time that lack of clinical fistula remission was documented.
Time frame: Time from treatment start to first visit when perianal fistula closure takes place of all external openings that were draining at baseline up to Week 24
Percentage of Participants Who Achieved Proctitis Remission at Week 24
The simple endoscopic score for Crohn's disease (SES-CD) score evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and presence of narrowings). The total SES-CD is calculated as the sum of the 4 variables for the required bowel segment. Values are given to each variable and for every examined bowel segment. The SES-CD size of ulcer subscore ranges from 0 (none) to 3 (very large) and for ulcerated surface subscore ranges from 0 (none) to 3 (\>30 % of affected area). Higher value of the subscore indicates disease worsening. Proctitis remission at Week 24 was defined as a proctitis SES-CD score (sum of ulcer size and ulcerated surface SES-CD endoscopy subscores for the rectum and anal canal) of 0 assessed by centrally read flexible sigmoidoscopy at Week 24, in participants that had moderately to severely active proctitis at baseline. Moderately to Severely Active Proctitis defined as proctitis SES-CD Score \> 2.
Time frame: Week 24
Participants were enrolled at study sites in Europe and the United States. The first participant was screened on 06 April 2017. The last study visit occurred on 17 February 2021.
| Milestone | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Started | 17 | 25 | 15 |
| Completed | 14 | 12 | 6 |
| Not completed | 3 | 13 | 9 |
| Withdrew: Non-responder [crohn's disease activity index (cdai) and perianal cdai non-response] at week 10 | 1 | 5 | 3 |
| Withdrew: Protocol-specified disease worsening | 1 | 3 | 3 |
| Withdrew: Adverse event | 1 | 2 | 2 |
| Withdrew: Investigator's discretion | 0 | 1 | 1 |
| Withdrew: Withdrew consent | 0 | 2 | 0 |
Combined fistula response at Week 24 was defined as reduction of greater than or equal to (≥) 1 from baseline in the number of draining external perianal fistula openings that were present at baseline, and absence of fluid collections \> 1 centimeter (cm) on magnetic resonance imaging (MRI) pelvis at Week 24, among participants with at least 1 draining external perianal fistula opening at baseline.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Combined Fistula Response at Week 24 | 47.1 (26.0 to 68.9) | 29.2 (14.6 to 47.9) | 25.0 (7.2 to 52.7) |
Combined fistula remission at Week 24 was defined as perianal fistula closure of all external openings that were draining at baseline, and absence of fluid collections \> 1 cm on MRI of pelvis at Week 24, among participants with at least 1 draining external perianal fistula opening at baseline.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Combined Fistula Remission at Week 24 | 47.1 (26.0 to 68.9) | 25.0 (11.5 to 43.5) | 16.7 (3.0 to 43.8) |
Time to clinical fistula response was defined as the time interval in days from date of first dosing of study drug to the first observation (during scheduled or unscheduled clinical visits) when ≥ 1 of the draining external perianal fistula openings that were present at baseline achieves perianal fistula closure, among participants with at least 1 draining external perianal fistula opening at baseline. Participants not known to had a clinical fistula response were to have their clinical fistula response time censored at the last time that lack of clinical fistula response was documented.
| days | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Time to Clinical Fistula Response up to Week 24 | 15 (15 to 28) | 16 (15 to 71) | 35.5 (15 to 71) |
Time to clinical fistula remission was defined as the time interval in days from date of first dosing of study drug to the first observation (during schedule or unscheduled clinical visits) of perianal fistula closure of all external openings that were draining at baseline, among participants with at least 1 draining external perianal fistula opening at baseline. Participants not known to had a clinical fistula remission were have their clinical fistula remission time censored at the last time that lack of clinical fistula remission was documented.
| days | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Time to Clinical Fistula Remission up to Week 24 | 15 (15 to 70) | 29 (16 to 74) | 71 (26 to NA) |
The simple endoscopic score for Crohn's disease (SES-CD) score evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and presence of narrowings). The total SES-CD is calculated as the sum of the 4 variables for the required bowel segment. Values are given to each variable and for every examined bowel segment. The SES-CD size of ulcer subscore ranges from 0 (none) to 3 (very large) and for ulcerated surface subscore ranges from 0 (none) to 3 (\>30 % of affected area). Higher value of the subscore indicates disease worsening. Proctitis remission at Week 24 was defined as a proctitis SES-CD score (sum of ulcer size and ulcerated surface SES-CD endoscopy subscores for the rectum and anal canal) of 0 assessed by centrally read flexible sigmoidoscopy at Week 24, in participants that had moderately to severely active proctitis at baseline. Moderately to Severely Active Proctitis defined as proctitis SES-CD Score \> 2.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Proctitis Remission at Week 24 | 10.0 (0.5 to 39.4) | 15.4 (2.8 to 41.0) | 28.6 (5.3 to 65.9) |
Collected over All-Cause Mortality: First dose date up to 24 weeks plus 30 days; Adverse Events: First dose date up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Filgotinib 200 mg | 0/17 (0%) | 5/17 (29.4%) | 13/17 (76.5%) |
| Filgotinib 100 mg | 0/25 (0%) | 2/25 (8%) | 14/25 (56%) |
| Placebo | 0/15 (0%) | 1/15 (6.7%) | 11/15 (73.3%) |
| Event | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 1/17 | 2/25 | 0/15 |
| Vulval abscessInfections and infestations | 0/17 | 0/25 | 1/15 |
| Intestinal obstructionGastrointestinal disorders | 1/17 | 0/25 | 0/15 |
| Large intestinal stenosisGastrointestinal disorders | 1/17 | 0/25 | 0/15 |
| BronchitisInfections and infestations | 1/17 | 0/25 | 0/15 |
| Suspected COVID-19Infections and infestations | 1/17 | 0/25 | 0/15 |
| Event | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| FatigueGeneral disorders | 3/17 | 3/25 | 0/15 |
| Anal abscessInfections and infestations | 3/17 | 0/25 | 1/15 |
| InfluenzaInfections and infestations | 3/17 | 1/25 | 2/15 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/17 | 2/25 | 0/15 |
| Anal fistulaGastrointestinal disorders | 2/17 | 2/25 | 2/15 |
| NasopharyngitisInfections and infestations | 2/17 | 2/25 | 2/15 |
| RashSkin and subcutaneous tissue disorders | 1/17 | 1/25 | 2/15 |
| Crohn's diseaseGastrointestinal disorders | 2/17 | 2/25 | 1/15 |
| NauseaGastrointestinal disorders | 2/17 | 2/25 | 1/15 |
| Oral herpesInfections and infestations | 2/17 | 0/25 | 1/15 |
| Age, Continuous(years) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 39 ± 11.2 | 41 ± 14.0 | 39 ± 11.8 | 40 ± 12.5 |
| Sex: Female, Male(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 9 | 10 | 4 | 23 |
| Male | 8 | 15 | 11 | 34 |
| Race/Ethnicity, Customized(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race — Asian | 0 | 2 | 0 | 2 |
| Race — Black or African American | 1 | 2 | 1 | 4 |
| Race — Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 |
| Race — White | 15 | 19 | 14 | 48 |
| Race — Other | 0 | 0 | 0 | 0 |
| Race — Not Permitted | 1 | 2 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Ethnicity — Not Hispanic or Latino | 17 | 23 | 15 | 55 |
| Ethnicity — Hispanic or Latino | 0 | 1 | 0 | 1 |
| Ethnicity — Not Permitted | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Canada | 1 | 3 | 1 | 5 |
| Austria | 4 | 2 | 2 | 8 |
| Belgium | 1 | 1 | 1 | 3 |
| Hungary | 1 | 1 | 1 | 3 |
| United States | 4 | 15 | 8 | 27 |
| United Kingdom | 1 | 0 | 0 | 1 |
| Italy | 0 | 0 | 1 | 1 |
| France | 2 | 3 | 0 | 5 |
| Germany | 3 | 0 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Jan 2021, 45 months.
Results were first posted in Apr 2022, 1 year 2 months after primary completion. A results delay was requested in Oct 2021.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 45 months is above that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634